13F Holdings
中文EN

STEK Stemtech Corp

Wholesale-Drugs, Proprietaries & Druggists' Sundries · OTC · SEC CIK 1511820 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.9%
TTM net income YoY-18.7%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-26.6%
Net income 3-yr CAGR—

Margins

Gross margin75.7%
Operating margin-134.0%
Net margin-191.3%
FCF margin-35.5%
EBITDA margin-124.8%

Returns

ROE—
ROA-102.2%
ROIC (approx.)—
Asset turnover0.53x

Leverage & solvency

Liabilities / assets361.0%
Debt / equity—
Current ratio0.05x
Interest coverage-2.62x

Cash quality & payout

Operating cash flow / net income0.19x
Accruals ratio-83.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.88M$5.05M$4.92M$4.56M$4.32M
Cost of revenue$566,940$1.33M$1.00M$1.16M$1.02M
Gross profit$2.31M$3.73M$3.92M$3.40M$3.30M
R&D expense$0$0$13,800$0—
SG&A expense$4.55M$5.23M$6.44M$6.84M$4.75M
Operating income-$2.71M-$2.39M-$4.22M-$5.02M-$3.21M
Interest expense$1.45M$1.58M$4.89M—$8.33M
Pretax income-$4.05M-$3.77M-$5.43M-$8.54M-$7.11M
Income tax$0$0$0$95,618$0
Net income-$4.05M-$3.77M-$5.43M-$8.54M-$7.08M
EBITDA-$2.54M-$2.04M-$3.64M-$4.58M-$2.78M
EPS (basic)-0.02-0.03-0.07-0.19-0.20
EPS (diluted)-0.02-0.03-0.07-0.19-0.20
Weighted avg. shares (diluted)169.82M118.70M83.47M46.01M35.31M
Balance sheet
Cash & equivalents$238,245$255,298$114,166$132,487$828,206
Inventory$217,338$197,355$48,325$158,053$436,405
Current assets$457,062$921,746$400,710$612,370$1.60M
PP&E, net$0$0$10,056$27,296$33,168
Goodwill$467,409$467,409$467,409$467,409$467,409
Intangibles$2.21M$2.38M$2.71M$2.99M$3.41M
Total assets$3.15M$3.78M$3.68M$4.27M$5.72M
Current liabilities$10.59M$8.74M$6.46M$7.42M$9.39M
Long-term debt$4.16M$3.82M$3.49M$929,131—
Total debt$4.16M$3.82M$3.49M$929,131—
Total liabilities$10.59M$8.74M$6.46M$7.44M$9.73M
Shareholders' equity-$6.96M-$4.48M-$2.04M-$2.43M-$3.36M
Net debt$3.92M$3.56M$3.37M$796,644—
Shares outstanding425.98M135.76M104.99M53.44M44.69M
Cash flow statement
Operating cash flow-$483,583-$601,198-$2.04M-$1.22M-$1.91M
Capital expenditure$0$0$0——
Free cash flow-$483,583-$601,198-$2.04M——
Investing cash flow$0$0$0——
Financing cash flow$460,010$1.08M$1.58M$338,734$2.63M
Depreciation & amortization$167,495$344,466$587,797$447,386$428,586
Stock-based compensation$439,054$440,256$439,054$4.00M$1.03M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.